Iron chelation therapy in myelodysplastic syndromes

Fausel, Christopher A.
April 2010
American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS10
Academic Journal
Purpose. To understand how to appropriately recognize and manage iron overload with iron chelation therapy (ICT) in patients with myelodysplastic syndromes (MDS), evaluation of the role of different agents available for management of iron overload, including efficacy, safety, and economic considerations for transfusion-dependent patients with MDS, is provided. Summary. Patients with MDS have a high incidence of anemia, which often requires treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are mainstays of therapy. Use of long-term transfusion therapy has limitations in patients with MDS due to the risk of developing iron overload. Strategies to manage iron overload include phlebotomy and ICT with agents such as deferoxamine and deferasirox. Data evaluating pharmacologic therapy for treatment of iron overload in patients with MDS suggest timely intervention can mitigate the morbidity associated with this clinical syndrome. Conclusion. Development of practical management strategies to implement and optimize ICT using deferoxamine and deferasirox will be important to provide optimal care for transfusion-dependent patients with MDS.


Related Articles

  • Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Komrokji, R. S.; List, A. F. // Annals of Oncology;Jan2016, Vol. 27 Issue 1, p62 

    The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del(5q)) with or without additional...

  • Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Delforge, Michel; Selleslag, Dominik; Triffet, Agnès; Mineur, Philippe; Bries, Greet; Graux, Carlos; Trullemans, Fabienne; MacDonald, Karen; Abraham, Ivo; Pluymers, Wim; Ravoet, Christophe // Annals of Hematology;Jun2011, Vol. 90 Issue 6, p655 

    Transfusion dependency and iron overload are common among patients with myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with leukemic progression and shorter survival. Guidelines recommend iron chelation therapy to manage iron...

  • Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. IMPROTA, SALVATORE; VILLA, MARIA ROSARIA; VOLPE, ANTONIO; LOMBARDI, ANGELA; STIUSO, PAOLA; CANTORE, NICOLA; MASTRULLO, LUCIA // Oncology Letters;2013, Vol. 6 Issue 6, p1774 

    Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis that results in peripheral cytopenias. Anemia is the most common symptom of MDS and the majority of patients become transfusion-dependent with the risk of iron overload, which may lead to cardiac, hepatic and...

  • Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis. Li, Xiao; Song, Qiang; Chen, Yu; Chang, Chunkang; Wu, Dong; Wu, Lingyun; Su, Jiying; Zhang, Xi; Zhou, Liyu; Song, Luxi; Zhang, Zheng; Xu, Feng; Hou, Ming // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine...

  • Global increase in DNA methylation in patients with myelodysplastic syndrome. Römermann, D.; Hasemeier, B.; Metzig, K.; Göhring, G.; Schlegelberger, B.; Länger, F.; Kreipe, H.; Lehmann, U. // Leukemia (08876924);Oct2008, Vol. 22 Issue 10, p1954 

    The article reports on the significant increase of the DNA methylation in patients with myelodysplastic syndrome. It says that epigenetic aberrations are recognized as early events in the process of malignant transformation. It also says that gene specific hypermethylation occurs in the context...

  • Oral iron chelating drug: coming but not yet ready for clinical use. Hershko, Chaim // British Medical Journal (Clinical Research Edition);4/16/1988, Vol. 296 Issue 6629, p1081 

    Focuses on the applicability of oral iron chelating drugs for clinical purposes. Importance of iron as a catalyst evolution; Development of an oral iron chelating agent; Rediscovery of polyanionic amine.

  • Transfusion-related costs before and after treatment with azacitidine in higher-risk myelodysplastic syndrome. E. Tseng; Mittmann, N.; S. J. Seung; Callum, J.; Prica, A.; Wells, R. A.; T. Kim; Buckstein, R. // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 1, pe133 

    Background: This study's objective is to determine the transfusion resources utilized and cost of red blood cell (RBC) transfusions before and after azacitidine (AZA) treatment in patients with myelodysplastic syndrome (MDS). Methods: In a retrospective review, 51 patients with MDS treated with...

  • Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Weiss, Lilia; Gary, Dianna; Swern, Arlene S.; Freeman, John; Sugrue, Mary M. // Therapeutics & Clinical Risk Management;Sep2015, Vol. 11, p1355 

    Background: Lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (MDS). In clinical trials, rash was common, although severe rash was infrequent. To examine rash in patients with MDS treated with lenalidomide in the...

  • Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Valencia, A; Masala, E; Rossi, A; Martino, A; Sanna, A; Buchi, F; Canzian, F; Cilloni, D; Gaidano, V; Voso, M T; Kosmider, O; Fontenay, M; Gozzini, A; Bosi, A; Santini, V // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p621 

    The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30-40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics